Valneva SE

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

13 Nov 2024 11:45:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

12 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

07 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: October 31, 2024

06 Nov 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

21 Oct 2024 11:45:00 By Nasdaq GlobeNewswire

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

16 Oct 2024 11:45:00 By Nasdaq GlobeNewswire

Valneva Hosts Investor Day in New York City

10 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva SE - Declaration of shares and voting rights - September 30, 2024

04 Oct 2024 01:30:00 By Nasdaq GlobeNewswire

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

03 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

18 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

13 Sep 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

12 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: August 31, 2024

04 Sep 2024 12:00:00 By Nasdaq GlobeNewswire

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

03 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

13 Aug 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: July 31, 2024

06 Aug 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

01 Aug 2024 01:00:00 By Nasdaq GlobeNewswire

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

22 Jul 2024 01:00:00 By Nasdaq GlobeNewswire

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion  

17 Jul 2024 16:00:00 By Nasdaq GlobeNewswire

Declaration of shares and voting rights - Valneva SE - June 30, 2024

04 Jul 2024 12:00:00 By Nasdaq GlobeNewswire